Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HLA-A*24:02-restricted T-cell receptor (TCR) complex is a multi-subunit transmembrane signaling assembly found on T-lymphocytes that specifically recognizes antigenic peptides presented by the HLA-A*24:02 MHC class I molecule [1]. This HLA allele is one of the most common in East Asian populations, particularly in Japan, where it serves as a critical restriction element for the presentation of tumor-associated antigens [1]. The TCR complex consists of a variable alpha/beta heterodimer that confers antigen specificity and a set of invariant CD3 subunits (gamma, delta, epsilon, and zeta) that facilitate signal transduction [3]. In modern oncology, this complex is the cornerstone of TCR-engineered T-cell (TCR-T) therapies, where patient T-cells are modified to express a high-affinity TCR specific for antigens like WT1 or NY-ESO-1 presented by HLA-A*24:02 [2]. Upon engagement with the target peptide-MHC complex, the TCR triggers a robust immune response, leading to the targeted destruction of malignant cells through cytotoxic granule release and cytokine production [4]. The development of these receptors requires rigorous screening to ensure high specificity and to prevent cross-reactivity with similar peptides in healthy tissues, which can lead to severe adverse events [4].
Recognition of specific peptide-HLA-A*24:02 complexes on target cells, triggering T-cell activation and cytotoxic effector functions [3, 4].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA-A*24:02-restricted T-cell receptor complex (HLA-A*24:02 TCR) (HLA-A*24:02 TCR).